Clinical Efficacy for Treatment of Patients with Peripheral T Cell Lymphoma by HyperCVAD and CHOP/CHOP-like Protocols.
- Author:
Rong-Hua CHEN
1
;
Shu-Xia GUO
2
;
Xiao-Juan ZHANG
2
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cyclophosphamide; therapeutic use; Dexamethasone; therapeutic use; Doxorubicin; therapeutic use; Humans; Lymphoma, T-Cell, Peripheral; drug therapy; Neutropenia; complications; Prednisone; therapeutic use; Remission Induction; Survival Rate; Treatment Outcome; Vincristine; therapeutic use
- From: Journal of Experimental Hematology 2016;24(1):80-83
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the clinical efficacy for treatment of patients with peripheral T cell lymphoma (PTCL) by HyperCVAD and CHOPCHOP-like protocols.
METHODSA total of 97 patients with peripheral T cell lymphoma were divided into observation group (50 cases) and control group (47 cases). The patients in observation group were treated by HyperCVAD, and the patients in the control group were treated by CHOP/CHOP-like protocol. The clinical efficacy, accumulate survival rate and side effect of the 2 groups were compared.
RESULTSThe remission rate in the observation group were higher than that in control group (P < 0.05); The PFS rate (1 year) in observation group was higher than that in control group (P < 0.05); the PFS rate (2 years, 3 years) was not significantly different (P > 0.05). The OS rate (1 year, 2 years, 3 years) did not show difference (P > 0.05); the number of patients with neutropenia in observation group was higher than that in control group (P < 0.05); the levels of CD4(+) CD45RA(+), CD4(+) CD45RO(+) in observation group were lower than those in control group (P < 0.05); the levels of CD4(+) and CD4(+)/CD8(+) in observation group was lower than those in control group (P < 0.05); the level of CD8(+) in observation group was higher than that in control group (P < 0.05); the incidence of pneumonia, cardiotoxicity, severe anemia, and thrombopenia were not significantly different (P > 0.05).
CONCLUSIONHypeCVAD protocol shows good clinical effects on the patients with peripheral T cell lymphoma, displaying a high remission rate and PFS rate (1 year), but it has a high incidence of neutropenia, thus it needs more attention in clinic.
